Thermo Fisher Scientific reports news across scientific instruments, laboratory equipment, diagnostics consumables, life science reagents and pharmaceutical services. Company updates commonly cover operating results, earnings calls, investor presentations and capital deployment through dividends, share repurchases and acquisitions.
Recurring developments also include collaborations tied to laboratory technologies, proteomics, biobank research, analytical instruments and biopharma customer services. Thermo Fisher’s brand portfolio includes Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD, and its completed Clario acquisition added endpoint data solutions for clinical trials to its Laboratory Products and Biopharma Services segment.
Thermo Fisher Scientific (NYSE: TMO) has launched a new cGMP plasmid DNA manufacturing facility in Carlsbad, California, addressing the rising demand for plasmid DNA-based therapies and mRNA vaccines. This 67,000-square-foot facility is part of a broader investment strategy aimed at ensuring high-quality materials for gene therapies. The expansion will create over 150 jobs and complements Thermo Fisher's existing infrastructure in various locations. CEO Marc N. Casper emphasized the necessity of this facility for the production of life-saving medicines.
Thermo Fisher Scientific (NYSE:TMO) announced an expansion of its partnership with My Green Lab to enhance sustainability in scientific research. The goal is to obtain the Accountability, Consistency and Transparency (ACT) labeling for its cold temperature storage portfolio by the end of 2021. Over 1,200 additional SKUs are expected to be labeled, thus aiding laboratories in sustainable purchasing. Thermo Fisher offers ENERGY STAR® certified freezers using eco-friendly refrigerants and aims for a 70% reduction in energy consumption compared to conventional alternatives.
Thermo Fisher Scientific (TMO) announced a quarterly cash dividend of $0.26 per common share, payable on October 15, 2021, to shareholders of record as of September 15, 2021. The company continues to showcase its commitment to rewarding shareholders, with annual revenue exceeding $30 billion. Thermo Fisher is recognized for its leadership in laboratory and pharmaceutical services, providing essential support across life sciences and diagnostics sectors.
Thermo Fisher Scientific (NYSE: TMO) will release its Q2 2021 financial results on July 28, 2021, before market opening. A conference call to discuss the results and future expectations will occur at 8:30 a.m. EDT on the same day. Investors can listen via phone or through the company's website. Thermo Fisher, a global leader in scientific services, has an annual revenue exceeding $30 billion and employs over 80,000 individuals worldwide.
Thermo Fisher Scientific (NYSE: TMO) announced a management change, with Alan Sachs transitioning to the role of chief medical officer and Karen E. Nelson appointed as chief scientific officer, effective August 2021. Sachs, who has been with the company since 2016, aims to enhance clinical strategy and support innovative product development. Nelson brings extensive experience from the J. Craig Venter Institute and a strong publication record. This leadership shift is designed to align R&D with evolving customer needs and bolster the company's commitment to advancing science.
Thermo Fisher Scientific and UC Davis announced the launch of the Center of Excellence in Clinical Metabolomics, aimed at advancing metabolomics research. This collaboration focuses on creating standard practices and protocols to enhance large cohort studies and clinical research. The center will utilize advanced Orbitrap technology for high-quality metabolic profiling and provide training for early-career scientists. Mark Stevenson emphasized the partnership's significance in refining techniques critical for clinical relevance.
Thermo Fisher Scientific (NYSE: TMO) will participate in the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021, at 9:40 a.m. EDT. Marc N. Casper, the CEO, will present virtually, with the webcast available on their website. Thermo Fisher, a leader in serving science with over $30 billion in annual revenue, supports various sectors, including life sciences and diagnostics. Their global team of over 80,000 employees provides innovative technologies and services through renowned brands.
Thermo Fisher Scientific (TMO) announced a quarterly cash dividend of $0.26 per common share, payable on July 15, 2021, to shareholders recorded by June 15, 2021. The company, a leader in serving science with over $30 billion in annual revenue, aims to support advancements in life sciences, diagnostics, and laboratory productivity. With a workforce of more than 80,000 employees, Thermo Fisher delivers innovative technologies through its renowned brands.
Thermo Fisher Scientific (NYSE:TMO) has partnered with the University of California, San Francisco (UCSF) to establish a cutting-edge cell therapy development and manufacturing facility. This 44,000-square-foot center will be located on UCSF's Mission Bay campus and is set to begin operations in 2022. The facility will provide clinical and commercial cGMP manufacturing services, enhancing access to Thermo Fisher's extensive Cell Therapy Systems portfolio. The collaboration aims to accelerate the development of innovative cell-based therapies, ultimately improving patient access to vital treatments.
Thermo Fisher Scientific will present at the BofA Securities 2021 Health Care Conference on May 12, 2021, at 8:45 a.m. EDT. The presentation will be virtual, led by Marc N. Casper, the company’s chairman and CEO. Investors can access the webcast on the company's website. Thermo Fisher, a leader in serving science, reported annual revenues exceeding $30 billion and employs over 80,000 people globally, offering innovative technologies and services across multiple brands.